Switch to:
Also traded in: Argentina, Brazil, France, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.52
LLY's Cash-to-Debt is ranked lower than
73% of the 827 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. LLY: 0.52 )
Ranked among companies with meaningful Cash-to-Debt only.
LLY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.11  Med: 0.71 Max: 1.71
Current: 0.52
0.11
1.71
Equity-to-Asset 0.35
LLY's Equity-to-Asset is ranked lower than
86% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. LLY: 0.35 )
Ranked among companies with meaningful Equity-to-Asset only.
LLY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.23  Med: 0.45 Max: 0.67
Current: 0.35
0.23
0.67
Debt-to-Equity 0.90
LLY's Debt-to-Equity is ranked lower than
81% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.30 vs. LLY: 0.90 )
Ranked among companies with meaningful Debt-to-Equity only.
LLY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.11  Med: 0.5 Max: 1.55
Current: 0.9
0.11
1.55
Debt-to-EBITDA 2.98
LLY's Debt-to-EBITDA is ranked lower than
62% of the 503 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. LLY: 2.98 )
Ranked among companies with meaningful Debt-to-EBITDA only.
LLY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.75  Med: 0.99 Max: 241.62
Current: 2.98
0.75
241.62
Interest Coverage 16.91
LLY's Interest Coverage is ranked lower than
65% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 106.84 vs. LLY: 16.91 )
Ranked among companies with meaningful Interest Coverage only.
LLY' s Interest Coverage Range Over the Past 10 Years
Min: 16.91  Med: 21.38 Max: 35.18
Current: 16.91
16.91
35.18
Piotroski F-Score: 6
Altman Z-Score: 3.48
Beneish M-Score: -2.74
WACC vs ROIC
2.93%
11.79%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 16.07
LLY's Operating Margin % is ranked higher than
74% of the 781 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.94 vs. LLY: 16.07 )
Ranked among companies with meaningful Operating Margin % only.
LLY' s Operating Margin % Range Over the Past 10 Years
Min: -6.29  Med: 21.98 Max: 28.28
Current: 16.07
-6.29
28.28
Net Margin % 9.90
LLY's Net Margin % is ranked higher than
67% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.12 vs. LLY: 9.90 )
Ranked among companies with meaningful Net Margin % only.
LLY' s Net Margin % Range Over the Past 10 Years
Min: -10.17  Med: 16.88 Max: 21.97
Current: 9.9
-10.17
21.97
ROE % 15.32
LLY's ROE % is ranked higher than
78% of the 803 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.08 vs. LLY: 15.32 )
Ranked among companies with meaningful ROE % only.
LLY' s ROE % Range Over the Past 10 Years
Min: -20.47  Med: 26.51 Max: 53.25
Current: 15.32
-20.47
53.25
ROA % 5.62
LLY's ROA % is ranked higher than
64% of the 831 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.77 vs. LLY: 5.62 )
Ranked among companies with meaningful ROA % only.
LLY' s ROA % Range Over the Past 10 Years
Min: -7.39  Med: 12.05 Max: 17.34
Current: 5.62
-7.39
17.34
ROC (Joel Greenblatt) % 31.38
LLY's ROC (Joel Greenblatt) % is ranked higher than
79% of the 817 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.08 vs. LLY: 31.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
LLY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -10.98  Med: 52.57 Max: 71.98
Current: 31.38
-10.98
71.98
3-Year Revenue Growth Rate -2.10
LLY's 3-Year Revenue Growth Rate is ranked lower than
74% of the 674 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. LLY: -2.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
LLY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -5.7  Med: 6.9 Max: 14.3
Current: -2.1
-5.7
14.3
3-Year EBITDA Growth Rate -9.40
LLY's 3-Year EBITDA Growth Rate is ranked lower than
80% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.20 vs. LLY: -9.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
LLY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -76.9  Med: 2.4 Max: 437.2
Current: -9.4
-76.9
437.2
3-Year EPS without NRI Growth Rate -15.80
LLY's 3-Year EPS without NRI Growth Rate is ranked lower than
79% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. LLY: -15.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
LLY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -26.4  Med: 2.8 Max: 54.9
Current: -15.8
-26.4
54.9
GuruFocus has detected 10 Warning Signs with Eli Lilly and Co LLY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» LLY's 30-Y Financials

Financials (Next Earnings Date: 2018-01-31)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

LLY Guru Trades in Q4 2016

Joel Greenblatt 38,305 sh (New)
Ray Dalio 119,400 sh (+500.57%)
Paul Tudor Jones 18,158 sh (+124.17%)
Pioneer Investments 1,374,165 sh (+81.02%)
Jim Simons 1,539,200 sh (+66.91%)
Sarah Ketterer 3,101,165 sh (+34.05%)
Manning & Napier Advisors, Inc 22,216 sh (+11.16%)
Ken Fisher 2,314,764 sh (+10.42%)
Vanguard Health Care Fund 27,339,210 sh (+5.31%)
Jeremy Grantham 1,085,111 sh (+3.61%)
Mairs and Power 250,478 sh (+3.43%)
PRIMECAP Management 57,501,098 sh (+1.86%)
HOTCHKIS & WILEY 26,900 sh (unchged)
Steven Cohen 1,000,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 881,915 sh (unchged)
David Dreman Sold Out
John Paulson Sold Out
Andreas Halvorsen Sold Out
Mario Gabelli 80,550 sh (-1.83%)
Dodge & Cox 28,597 sh (-2.51%)
Murray Stahl 26,616 sh (-6.99%)
Steven Cohen 6,900 sh (-97.76%)
» More
Q1 2017

LLY Guru Trades in Q1 2017

George Soros 3,900 sh (New)
Steven Cohen 902,600 sh (+12981.16%)
Joel Greenblatt 448,591 sh (+1071.10%)
Mairs and Power 719,208 sh (+187.13%)
Jim Simons 2,980,400 sh (+93.63%)
Manning & Napier Advisors, Inc 27,277 sh (+22.78%)
Ken Fisher 2,581,462 sh (+11.52%)
HOTCHKIS & WILEY 26,900 sh (unchged)
Steven Cohen 100,000 sh (unchged)
Ray Dalio Sold Out
PRIMECAP Management 57,129,705 sh (-0.65%)
Vanguard Health Care Fund 27,091,270 sh (-0.91%)
Mario Gabelli 79,100 sh (-1.80%)
Pioneer Investments 1,306,010 sh (-4.96%)
Dodge & Cox 26,997 sh (-5.59%)
Murray Stahl 25,091 sh (-5.73%)
Sarah Ketterer 2,405,934 sh (-22.42%)
Jeremy Grantham 838,219 sh (-22.75%)
Paul Tudor Jones 4,000 sh (-77.97%)
Eaton Vance Worldwide Health Sciences Fund 792,297 sh (-10.16%)
» More
Q2 2017

LLY Guru Trades in Q2 2017

Ray Dalio 51,151 sh (New)
Dodge & Cox 5,991,952 sh (+22094.88%)
Jim Simons 5,694,905 sh (+91.08%)
Steven Cohen 1,278,149 sh (+41.61%)
Sarah Ketterer 3,269,253 sh (+35.88%)
Mairs and Power 871,836 sh (+21.22%)
Ken Fisher 2,989,521 sh (+15.81%)
Vanguard Health Care Fund 28,073,170 sh (+3.62%)
Jeremy Grantham 867,273 sh (+3.47%)
Murray Stahl 25,447 sh (+1.42%)
HOTCHKIS & WILEY 26,900 sh (unchged)
George Soros Sold Out
PRIMECAP Management 56,362,580 sh (-1.34%)
Mario Gabelli 76,800 sh (-2.91%)
Manning & Napier Advisors, Inc 24,802 sh (-9.07%)
Paul Tudor Jones 2,968 sh (-25.80%)
Pioneer Investments 937,650 sh (-28.20%)
Joel Greenblatt 8,999 sh (-97.99%)
Eaton Vance Worldwide Health Sciences Fund 645,890 sh (-18.48%)
» More
Q3 2017

LLY Guru Trades in Q3 2017

Dodge & Cox 20,020,077 sh (+234.12%)
Mairs and Power 976,949 sh (+12.06%)
Ken Fisher 3,109,012 sh (+4.00%)
Vanguard Health Care Fund 28,110,470 sh (+0.13%)
Ray Dalio Sold Out
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 55,682,522 sh (-1.21%)
Murray Stahl 25,082 sh (-1.43%)
HOTCHKIS & WILEY 26,200 sh (-2.60%)
Mario Gabelli 73,850 sh (-3.84%)
Manning & Napier Advisors, Inc 23,077 sh (-6.96%)
Pioneer Investments 868,850 sh (-7.34%)
Jeremy Grantham 802,049 sh (-7.52%)
Sarah Ketterer 3,007,960 sh (-7.99%)
Jim Simons 4,049,205 sh (-28.90%)
Steven Cohen 600,000 sh (-53.06%)
Eaton Vance Worldwide Health Sciences Fund 590,237 sh (-8.62%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:LLY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2017-09-30 Add 0.13%0.01%$77.07 - $85.54 $ 86.495%28,110,470
Dodge & Cox 2017-09-30 Add 234.12%0.97%$77.07 - $85.54 $ 86.495%20,020,077
Ken Fisher 2017-09-30 Add 4.00%0.01%$77.07 - $85.54 $ 86.495%3,109,012
Mario Gabelli 2017-09-30 Reduce -3.84%$77.07 - $85.54 $ 86.495%73,850
HOTCHKIS & WILEY 2017-09-30 Reduce -2.60%$77.07 - $85.54 $ 86.495%26,200
Joel Greenblatt 2017-09-30 Sold Out 0.01%$77.07 - $85.54 $ 86.495%0
Vanguard Health Care Fund 2017-06-30 Add 3.62%0.17%$76.98 - $86.25 $ 86.496%28,073,170
Dodge & Cox 2017-06-30 Add 22094.88%0.42%$76.98 - $86.25 $ 86.496%5,991,952
Ken Fisher 2017-06-30 Add 15.81%0.05%$76.98 - $86.25 $ 86.496%2,989,521
Mario Gabelli 2017-06-30 Reduce -2.91%$76.98 - $86.25 $ 86.496%76,800
Joel Greenblatt 2017-06-30 Reduce -97.99%0.47%$76.98 - $86.25 $ 86.496%8,999
George Soros 2017-06-30 Sold Out 0.01%$76.98 - $86.25 $ 86.496%0
Vanguard Health Care Fund 2017-03-31 Reduce -0.91%0.04%$74.58 - $85.88 $ 86.498%27,091,270
Ken Fisher 2017-03-31 Add 11.52%0.04%$74.58 - $85.88 $ 86.498%2,581,462
Joel Greenblatt 2017-03-31 Add 1071.10%0.44%$74.58 - $85.88 $ 86.498%448,591
Mario Gabelli 2017-03-31 Reduce -1.80%$74.58 - $85.88 $ 86.498%79,100
Dodge & Cox 2017-03-31 Reduce -5.59%$74.58 - $85.88 $ 86.498%26,997
George Soros 2017-03-31 New Buy0.01%$74.58 - $85.88 $ 86.498%3,900
Vanguard Health Care Fund 2016-12-31 Add 5.31%0.24%$65.97 - $83.06 $ 86.4916%27,339,210
Ken Fisher 2016-12-31 Add 10.42%0.03%$65.97 - $83.06 $ 86.4916%2,314,764
Mario Gabelli 2016-12-31 Reduce -1.83%$65.97 - $83.06 $ 86.4916%80,550
Joel Greenblatt 2016-12-31 New Buy0.04%$65.97 - $83.06 $ 86.4916%38,305
Dodge & Cox 2016-12-31 Reduce -2.51%$65.97 - $83.06 $ 86.4916%28,597
John Paulson 2016-12-31 Sold Out 0.04%$65.97 - $83.06 $ 86.4916%0
David Dreman 2016-12-31 Sold Out 0.04%$65.97 - $83.06 $ 86.4916%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:BMY, LSE:GSK, LSE:AZN, XTER:BAYN, XPAR:SAN, NYSE:MRK, NYSE:ABBV, TSE:4519, TSE:4503, TSE:4578, TSE:4568, HKSE:01093, TSE:4528, TSE:4151, MIL:REC, BOM:500087, BOM:500302, XKRX:008930, TSE:4536, SHSE:600867 » details
Traded in other countries:LLY.Argentina, LILY34.Brazil, LLY.France, LLY.Germany, LLY.Mexico, LLY.Switzerland, LEL.UK,
Headquarter Location:USA
Eli Lilly and Co is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. It discovers, develops, manufactures, and sells human pharmaceutical products and animal health products.

Eli Lilly is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta for cancer; Forteo for osteoporosis; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Cialis for erectile dysfunction. Also, Lilly holds a strong position in the animal healthcare market.

Top Ranked Articles about Eli Lilly and Co

Rimidi and Lilly Collaborate to Personalize Solutions for People Using Insulin
Lilly Announces 2018 Financial Guidance and Enhances Outlook Through 2020
Lilly Announces 8 Percent Dividend Increase
Kimberly Blackwell, M.D., to become Vice President of Early Phase Development and Immuno-oncology at Lilly Oncology
FDA Accepts Biologics License Application (BLA) to Review Galcanezumab for the Prevention of Migraine in Adults
Lilly Reports Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 Study in First-Line Advanced Gastric Cancer
Lilly Initiates Clinical Trial to Evaluate the Functionality and Safety of its Automated Insulin Delivery System
Detailed Research: Economic Perspectives on TiVo, Eli Lilly, Rigel Pharmaceuticals, SpartanNash, Nustar GP, and Hornbeck Offshore Services — What Drives Growth in Today's Competitive Landscape
Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Active Psoriatic Arthritis
9 Positions Dodge & Cox Increased in the Past 2 Quarters Eli Lilly, Target among firm's investments
Van Duyn Dodge and E. Morris Cox founded Dodge & Cox in 1930. In both the second and third quarters, the firm invested in the following stocks: Read more...

Ratios

vs
industry
vs
history
PE Ratio 40.98
LLY's PE Ratio is ranked lower than
68% of the 570 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.41 vs. LLY: 40.98 )
Ranked among companies with meaningful PE Ratio only.
LLY' s PE Ratio Range Over the Past 10 Years
Min: 7.44  Med: 16.36 Max: 45.75
Current: 40.98
7.44
45.75
Forward PE Ratio 18.62
LLY's Forward PE Ratio is ranked higher than
51% of the 74 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.53 vs. LLY: 18.62 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 40.98
LLY's PE Ratio without NRI is ranked lower than
68% of the 566 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.56 vs. LLY: 40.98 )
Ranked among companies with meaningful PE Ratio without NRI only.
LLY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 7.44  Med: 16.36 Max: 45.75
Current: 40.98
7.44
45.75
Price-to-Owner-Earnings 31.14
LLY's Price-to-Owner-Earnings is ranked higher than
56% of the 310 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.43 vs. LLY: 31.14 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
LLY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 6.36  Med: 14.15 Max: 159.16
Current: 31.14
6.36
159.16
PB Ratio 6.40
LLY's PB Ratio is ranked lower than
83% of the 798 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.86 vs. LLY: 6.40 )
Ranked among companies with meaningful PB Ratio only.
LLY' s PB Ratio Range Over the Past 10 Years
Min: 2.52  Med: 4.18 Max: 6.85
Current: 6.4
2.52
6.85
PS Ratio 4.07
LLY's PS Ratio is ranked lower than
61% of the 756 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.79 vs. LLY: 4.07 )
Ranked among companies with meaningful PS Ratio only.
LLY' s PS Ratio Range Over the Past 10 Years
Min: 1.49  Med: 2.7 Max: 4.81
Current: 4.07
1.49
4.81
Price-to-Free-Cash-Flow 24.13
LLY's Price-to-Free-Cash-Flow is ranked higher than
52% of the 212 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.72 vs. LLY: 24.13 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
LLY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.17  Med: 13.6 Max: 56.76
Current: 24.13
5.17
56.76
Price-to-Operating-Cash-Flow 15.57
LLY's Price-to-Operating-Cash-Flow is ranked higher than
56% of the 290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.64 vs. LLY: 15.57 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
LLY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.41  Med: 10.95 Max: 31.12
Current: 15.57
4.41
31.12
EV-to-EBIT 33.73
LLY's EV-to-EBIT is ranked lower than
71% of the 572 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.28 vs. LLY: 33.73 )
Ranked among companies with meaningful EV-to-EBIT only.
LLY' s EV-to-EBIT Range Over the Past 10 Years
Min: -303.9  Med: 11.95 Max: 37.4
Current: 33.73
-303.9
37.4
EV-to-EBITDA 22.54
LLY's EV-to-EBITDA is ranked lower than
63% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.61 vs. LLY: 22.54 )
Ranked among companies with meaningful EV-to-EBITDA only.
LLY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.8  Med: 12.15 Max: 1132
Current: 22.54
4.8
1132
EV-to-Revenue 4.53
LLY's EV-to-Revenue is ranked lower than
62% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.07 vs. LLY: 4.53 )
Ranked among companies with meaningful EV-to-Revenue only.
LLY' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.6  Med: 2.7 Max: 5
Current: 4.53
1.6
5
Shiller PE Ratio 28.87
LLY's Shiller PE Ratio is ranked higher than
63% of the 204 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.18 vs. LLY: 28.87 )
Ranked among companies with meaningful Shiller PE Ratio only.
LLY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 10.83  Med: 18.34 Max: 29.34
Current: 28.87
10.83
29.34
Current Ratio 1.38
LLY's Current Ratio is ranked lower than
76% of the 738 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.53 vs. LLY: 1.38 )
Ranked among companies with meaningful Current Ratio only.
LLY' s Current Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.58 Max: 3
Current: 1.38
0.7
3
Quick Ratio 1.03
LLY's Quick Ratio is ranked lower than
76% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.94 vs. LLY: 1.03 )
Ranked among companies with meaningful Quick Ratio only.
LLY' s Quick Ratio Range Over the Past 10 Years
Min: 0.53  Med: 1.22 Max: 2.38
Current: 1.03
0.53
2.38
Days Inventory 249.83
LLY's Days Inventory is ranked lower than
90% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 120.98 vs. LLY: 249.83 )
Ranked among companies with meaningful Days Inventory only.
LLY' s Days Inventory Range Over the Past 10 Years
Min: 173.48  Med: 209.47 Max: 249.83
Current: 249.83
173.48
249.83
Days Sales Outstanding 71.49
LLY's Days Sales Outstanding is ranked higher than
51% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.92 vs. LLY: 71.49 )
Ranked among companies with meaningful Days Sales Outstanding only.
LLY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 49.79  Med: 54.75 Max: 71.49
Current: 71.49
49.79
71.49
Days Payable 74.10
LLY's Days Payable is ranked higher than
57% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 68.69 vs. LLY: 74.10 )
Ranked among companies with meaningful Days Payable only.
LLY' s Days Payable Range Over the Past 10 Years
Min: 73.87  Med: 83.36 Max: 96.97
Current: 74.1
73.87
96.97

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.40
LLY's Dividend Yield % is ranked higher than
83% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. LLY: 2.40 )
Ranked among companies with meaningful Dividend Yield % only.
LLY' s Dividend Yield % Range Over the Past 10 Years
Min: 2.24  Med: 3.62 Max: 6.79
Current: 2.4
2.24
6.79
Dividend Payout Ratio 0.99
LLY's Dividend Payout Ratio is ranked lower than
82% of the 416 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. LLY: 0.99 )
Ranked among companies with meaningful Dividend Payout Ratio only.
LLY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.43  Med: 0.54 Max: 0.99
Current: 0.99
0.43
0.99
3-Year Dividend Growth Rate 1.30
LLY's 3-Year Dividend Growth Rate is ranked lower than
64% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. LLY: 1.30 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
LLY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 7 Max: 20.2
Current: 1.3
0
20.2
Forward Dividend Yield % 2.56
LLY's Forward Dividend Yield % is ranked higher than
68% of the 679 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.05 vs. LLY: 2.56 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.47
LLY's 5-Year Yield-on-Cost % is ranked higher than
71% of the 849 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.98 vs. LLY: 2.47 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
LLY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.33  Med: 3.77 Max: 7.07
Current: 2.47
2.33
7.07
3-Year Average Share Buyback Ratio 0.50
LLY's 3-Year Average Share Buyback Ratio is ranked higher than
90% of the 522 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.80 vs. LLY: 0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LLY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.1  Med: -0.1 Max: 2
Current: 0.5
-3.1
2

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 15.23
LLY's Price-to-Tangible-Book is ranked lower than
93% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.49 vs. LLY: 15.23 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
LLY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.22  Med: 6.68 Max: 33.46
Current: 15.23
3.22
33.46
Price-to-Intrinsic-Value-Projected-FCF 1.98
LLY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
57% of the 306 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.32 vs. LLY: 1.98 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
LLY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.68  Med: 2.1 Max: 5.56
Current: 1.98
0.68
5.56
Price-to-Median-PS-Value 1.51
LLY's Price-to-Median-PS-Value is ranked lower than
79% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.04 vs. LLY: 1.51 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
LLY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.6  Med: 1.49 Max: 4
Current: 1.51
0.6
4
Price-to-Graham-Number 5.27
LLY's Price-to-Graham-Number is ranked lower than
89% of the 438 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.97 vs. LLY: 5.27 )
Ranked among companies with meaningful Price-to-Graham-Number only.
LLY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.25  Med: 2.78 Max: 8.41
Current: 5.27
1.25
8.41
Earnings Yield (Greenblatt) % 2.95
LLY's Earnings Yield (Greenblatt) % is ranked higher than
51% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.23 vs. LLY: 2.95 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
LLY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2.9  Med: 6.55 Max: 17.4
Current: 2.95
-2.9
17.4
Forward Rate of Return (Yacktman) % -6.16
LLY's Forward Rate of Return (Yacktman) % is ranked lower than
81% of the 397 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.07 vs. LLY: -6.16 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
LLY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -17  Med: 5 Max: 72
Current: -6.16
-17
72

More Statistics

Revenue (TTM) (Mil) $22,471.10
EPS (TTM) $ 2.11
Beta0.11
Short Percentage of Float1.33%
52-Week Range $65.66 - 89.09
Shares Outstanding (Mil)1,101.09

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 22,630 23,158 23,318 24,261
EPS ($) 4.20 4.67 5.05 5.90
EPS without NRI ($) 4.20 4.67 5.05 5.90
EPS Growth Rate
(Future 3Y To 5Y Estimate)
11.58%
Dividends per Share ($) 2.12 2.28 2.29

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}